In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Riquent "Approvable" For Lupus; FDA Says Ongoing Study Could Be Enough

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

La Jolla Pharmaceuticals hopes running a parallel study alongside the ongoing confirmatory trial for its lupus agent Riquent will satisfy the requirements set out in FDA’s Oct. 14 "approvable" letter.

You may also be interested in...



BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial

With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010

La Jolla reactivates Phase III Riquent trial

La Jolla has reactivated enrollment in a Phase III trial of Riquent (abetimus sodium) in lupus renal disease under a special protocol assessment. The trial is being conducted at FDA's request based on clinical deficiencies relating to the firm's previous Phase II and Phase III trials cited in an October 2004 "approvable" letter (1Pharmaceutical Approvals Monthly November 2004, p. 13). FDA recommended another study to distinguish Riquent from placebo through an endpoint such as time to renal flare. La Jolla plans to enroll 600 patients by the second half of 2007 and has expanded the trial to include Europe and Mexico...

Genelabs Prestara update

Genelabs plans to meet with FDA "to discuss the company's options with regard to the development of Prestara [prasterone] for lupus," the firm says June 22. Future development of Prestara also hinges on the outcome of an open-label extension study of a failed confirmatory trial looking at the agent's effect on bone mineral density. The trial is slated to complete in August 2005. "While [the study] may provide useful data on the effect of Prestara on bone mineral density of women with lupus over a longer period of time, the FDA normally does not consider such open-label studies to be sufficient to support approval of a new drug," Genelabs noted. La Jolla is currently conducting a confirmatory trial for its lupus agent Riquent (abetimus) (1Pharmaceutical Approvals Monthly November 2004, p. 13); Immunomedics' monoclonal antibody epratuzumab recently entered Phase III for the autoimmune disease...

Related Content

Topics

UsernamePublicRestriction

Register

PS002710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel